Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0029421007
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG01223DLB2
AARD
Aardvark Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Software - Application · THEMEFOLIO: $HLTH
NAME
Aardvark Therapeutics Inc
ISIN
US0029421007
TICKER
AARD
MIC
XNAS
REUTERS
AARD.OQ
BLOOMBERG
AARD US
Mi., 02.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 01.09.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Sept. 1, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 01.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 1, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 01.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's F...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 31.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 31.08.2026       Aardvark Therapeutics
US0029421007

Lead Plaintiff Deadline October 13, 2026NEW YORK and SAN DIEGO, Aug. 31, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the announces that a securities class action lawsuit has been fi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 30.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvar...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 29.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Aardvark to Contact Him Directly to Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 29, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 13, 2026 deadline...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 29.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvar...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 28.08.2026       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 28, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b)...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 28.08.2026       Aardvark Therapeutics
US0029421007

BENSALEM, Pa., Aug. 28, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK THERAPEUTICS, INC. (AARD), CONTACT THE LAW OFFICES OF HOWARD G...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 28.08.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 28.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 28, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 28.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvar...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 27.08.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and certain officers and directors. The class action, filed in the United States District Court for the Southern District of California, and docketed under 26-cv...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 27.08.2026       Aardvark Therapeutics
US0029421007

LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Aardvark Therapeutics, Inc. (AARD) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK TH...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 27.08.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 init...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 27.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 27.08.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges Aardvark Therapeutics' Chief Executive Officer, Chief Financial Officer, and former Chief Operating Officer controlled the safety representations about ARD-101 that preceded a Phase 3 pause and a full FDA clinical hold.AARD INVESTOR ALERTNEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt alerts investors in Aardvar...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 27.08.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges Aardvark Therapeutics' Chief Executive Officer, Chief Financial Officer, and former Chief Operating Officer controlled the safety representations about ARD-101 that preceded a Phase 3 pause and a full FDA clinical hold.AARD INVESTOR ALERTNEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt alerts investors in Aardvar...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 27.08.2026       Aardvark Therapeutics
US0029421007

San Francisco, California--(Newsfile Corp. - August 27, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documen...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 27.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvar...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 26.08.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 26.08.2026       Aardvark Therapeutics
US0029421007

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 13, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) securities between February 10, 2025 and May 14, 2026 inclusi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 26.08.2026       Aardvark Therapeutics
US0029421007

Law Offices of Howard G. Smith reminds investors of the upcoming October 13, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) securities between February 10, 2025 and May 14, 2026, inclusive (the “Class Period”).IF YOU ARE AN...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 26.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 26.08.2026       Aardvark Therapeutics
US0029421007

Aardvark Therapeutics' shares lost more than 70% of their IPO value across two market events after the Company disclosed a Phase 3 safety pause and then a full FDA clinical hold on ARD-101, which a securities class action alleges corrected earlier representations that the drug was "99% gut-restricted" with minimal systemic exposure.NEW YORK, Aug....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 26.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvar...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 25.08.2026       Aardvark Therapeutics
US0029421007

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 13, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) securities between February 10, 2025 and May 14, 2026, inclusi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 25.08.2026       Aardvark Therapeutics
US0029421007

Lead Plaintiff Deadline October 13, 2026NEW YORK and SAN DIEGO, Aug. 25, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the announces that a securities class action lawsuit has been fi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 25.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 25.08.2026       Aardvark Therapeutics
US0029421007

The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares in the U.S. District Court for the Southern District of California (No: 3:26-cv-04643). Investors, who purchased a significant amount of Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 13, 20...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 25.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Stateme...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 25.08.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 24.08.2026       Aardvark Therapeutics
US0029421007

San Diego, California--(Newsfile Corp. - August 24, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 24.08.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Aug. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 24.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 24.08.2026       Aardvark Therapeutics
US0029421007

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) securities between February 10, 2025 and May 14, 2026, inclu...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 24.08.2026       Aardvark Therapeutics
US0029421007

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) common stock between February 10, 2025 and May 14, 2026, inclusive (the “Class Period”). Aardvark investors have until October 13, 2026 to file a lead plain...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 24.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement")...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 23.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 22.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement")...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 22.08.2026       Aardvark Therapeutics
US0029421007

San Francisco, California--(Newsfile Corp. - August 21, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documen...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 21.08.2026       Aardvark Therapeutics
US0029421007

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) common stock between February 10, 2025 and May 14, 2026, inclusive (the “Class Period”). Aardvark investors have until October 1...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 21.08.2026       Aardvark Therapeutics
US0029421007

The DJS Law Group reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) violations of the federal securities laws.Shareholders who purchased shares of AARD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointme...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 21.08.2026       Aardvark Therapeutics
US0029421007

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up on October 31, 2026, in the lawsuit that was filed for certain investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD). Investors, who purchased shares in excess of $100,...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges Aardvark Therapeutics overstated ARD-101's safety profile; Wall Street price targets collapsed from as high as $29 to $7 after the Phase 3 HERO trial was paused and the FDA imposed a clinical hold.NEW YORK, Aug. 20, 2026 /PRNewswire/ -- SueWallSt tracks the reversal in Wall Street analyst opinion on Aardvark Thera...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers. This lawsuit seeks to...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 20, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink